A Pilot Study of Talazoparib as a Neoadjuvant Study in Patients With a Diagnosis of Invasive Breast Cancer and a Deleterious BRCA Mutation

Trial Profile

A Pilot Study of Talazoparib as a Neoadjuvant Study in Patients With a Diagnosis of Invasive Breast Cancer and a Deleterious BRCA Mutation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Talazoparib (Primary)
  • Indications Adenocarcinoma; Early breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Feb 2018 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
    • 03 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top